Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009

(2011) D.R. Snydman et al.   ANAEROBE

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

(2011) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14– and CTX-M-15–producing Escherichia coli and Klebsiella pneumoniae

(2011) Emilia Titelman et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Activity of a New Cephalosporin, CXA-101 (FR264205), against  -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Lessons Learned from the Anaerobe Survey: Historical Perspective and Review of the Most Recent Data (2005–2007)

(2010) David R. Snydman et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance

(2009) C. C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY